New combo therapy aims to control lung cancer spread in the chest
NCT ID NCT07482605
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 4 times
Summary
This study is for people with a specific type of lung cancer (EGFR-positive adenocarcinoma) that has spread to the lining of the chest, causing fluid buildup. Researchers are testing whether combining a daily targeted pill (furmonertinib) with focused chest radiation can safely control the cancer and fluid longer than the drug alone. About 63 participants will be followed to see how long the cancer stays under control and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- furmonertinib (a targeted cancer pill) and chest radiotherapy
- What this could lead to
- If successful, this combination could offer a new, more effective treatment option for people with EGFR-mutant lung cancer that has spread to the lining of the chest, potentially delaying disease progression.
- What could go wrong
- This is an early-phase trial with only 63 participants, so results may not apply to everyone. The combination may cause side effects like lung inflammation or fatigue, and it's not yet proven to be better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Family support may be key to easing lung cancer surgery stress
- Can a drop of blood predict disease years before it strikes?
- Blood, urine, and stool may hold the key to predicting a serious side effect of lung cancer treatment
- Microwave ablation vs. radiotherapy: which Non-Surgical option works best for early lung cancer?
- Double-Targeted therapy aims to outsmart Hard-to-Treat lung cancer